Targeting SDF-1/CXCR4 to inhibit tumour vasculature for treatment of glioblastomas. - Wikidata - wikimedia - TriplyDB

Targeting SDF-1/CXCR4 to inhibit tumour vasculature for treatment of glioblastomas.

Targeting SDF-1/CXCR4 to inhibit tumour vasculature for treatment of glioblastomas.

http://www.wikidata.org/entity/Q37876686

about

Glioma Stem Cells and Their Microenvironments: Providers of Challenging Therapeutic Targets The Tumor Macroenvironment: Cancer-Promoting Networks Beyond Tumor Beds Radiation therapy-induced tumor invasiveness is associated with SDF-1-regulated macrophage mobilization and vasculogenesis Phosphatidylcholine-specific phospholipase C inhibition down- regulates CXCR4 expression and interferes with proliferation, invasion and glycolysis in glioma cells.CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice Extravillous trophoblast and decidual natural killer cells: a remodelling partnership.Role of bone marrow-derived cells in angiogenesis: focus on macrophages and pericytes.MMP-2 suppression abrogates irradiation-induced microtubule formation in endothelial cells by inhibiting αvβ3-mediated SDF-1/CXCR4 signaling.Targeting CXCR4 by a selective peptide antagonist modulates tumor microenvironment and microglia reactivity in a human glioblastoma model S100B promotes glioma growth through chemoattraction of myeloid-derived macrophages Local CXCR4 Upregulation in the Injured Arterial Wall Contributes to Intimal Hyperplasia.Strategies for optimizing the response of cancer and normal tissues to radiation.Controlling escape from angiogenesis inhibitors.Modulation of tumor tolerance in primary central nervous system malignancies.The potential of carboxypeptidase M as a therapeutic target in cancer.New treatment strategies to eradicate cancer stem cells and niches in glioblastoma.Physiology and pharmacology of plerixafor.Chemokine receptor modeling: an interdisciplinary approach to drug design.CXCR4 as biomarker for radioresistant cancer stem cells.Cytokines: shifting the balance between glioma cells and tumor microenvironment after irradiation.Metastasis review: from bench to bedside.Opportunities and challenges of radiotherapy for treating cancer.The novel CXCR4 antagonist, PRX177561, reduces tumor cell proliferation and accelerates cancer stem cell differentiation in glioblastoma preclinical models.ROS-Induced CXCR4 Signaling Regulates Mantle Cell Lymphoma (MCL) Cell Survival and Drug Resistance in the Bone Marrow Microenvironment via Autophagy.CrkL regulates SDF-1-induced breast cancer biology through balancing Erk1/2 and PI3K/Akt pathways.Gr-1+CD11b+ cells facilitate Lewis lung cancer recurrence by enhancing neovasculature after local irradiation.Controlled delivery of SDF-1α and IGF-1: CXCR4(+) cell recruitment and functional skeletal muscle recovery.Changes in the Secretory Profile of NSCLC-Associated Fibroblasts after Ablative Radiotherapy: Potential Impact on Angiogenesis and Tumor Growth.Locoregional Confinement and Major Clinical Benefit of 188Re-Loaded CXCR4-Targeted Nanocarriers in an Orthotopic Human to Mouse Model of Glioblastoma.VEGF as a modulator of the innate immune response in glioblastoma.CXC motif ligand 12 as a novel diagnostic marker for papillary thyroid carcinoma.Axially vascularized tissue-engineered bone constructs retain their in vivo angiogenic and osteogenic capacity after high-dose irradiation.The Impact of Radiation on the Tumor Microenvironment: Effect of Dose and Fractionation Schedules.Microglia/Astrocytes-Glioblastoma Crosstalk: Crucial Molecular Mechanisms and Microenvironmental Factors

P2860

Q26765758-AA53A0AA-A7CB-45B9-A064-65198CEE73EF Q26799120-6E91E50B-362F-43B7-9C7F-FC685F0E2967 Q27311252-33C76FA6-394B-46E9-8B5D-17E1B92983FA Q33580152-C7D9C782-D52B-4D39-958C-FD8708FD55FE Q35528287-5B6404B6-F8D6-4814-A4CD-E7AF5D5F8629 Q36026812-E9C2E50A-CAAB-48DC-9602-4838F7A7BB92 Q36284948-68286833-714E-45FE-8617-3B67317C28CB Q36650689-C03E7718-358B-4EF9-87F3-D919BAC8BD29 Q36728282-DDDF917D-544A-4C62-8632-F8A73825BD79 Q37051646-7A22DA0A-F943-4CDB-BC0E-84B2EC7CDDA1 Q37420405-4940F0D6-4000-4FD0-8E86-2CA95B235534 Q37531724-95EF2BAC-F6B8-465D-8D27-EFE53DA317C2 Q37672654-4E4AAEDD-291F-4C5C-A288-124B5E13C59A Q37982065-EC8BB380-39F6-4528-ACC8-548DEBD635E3 Q38072098-0527203D-86B4-434D-838F-2FC5FDDCCA4A Q38154066-48F406E4-C26E-4654-BA1B-9913725A0F4A Q38157897-A4AE632B-B205-4AEA-AF08-645B4C5587ED Q38172960-A3ADFEAD-FDAC-4882-B401-B461ECC4C3ED Q38197709-AA15B18A-EA0E-4348-BDD3-D859B4BAA998 Q38227496-D0244B2A-93FA-42D5-B5D2-6F466FC6A154 Q38237985-E6AD60BD-AFD4-44CB-B280-A9355587A0B6 Q38539957-143ADCA8-88A1-4DD7-8EFF-C514241B33D1 Q38699394-10078B3F-3A8D-40B1-8A99-7427EA7238FF Q38836849-E7DF7661-6698-4D66-9F9D-C1AFCC1EC203 Q38932140-6149B542-02D2-40D4-80A0-43DC13FA1E12 Q39030742-523EA52B-C348-4B5E-BD70-10EFFC219F8A Q40654214-2B3F3986-6049-4E0B-8699-33E1B5F93046 Q41810070-2BF9D60C-DF39-46F5-888C-F69B1A79E799 Q44243239-430A6EBD-FA8F-44B9-B85B-FEFFF346C6DC Q48289579-3D62D041-4AD7-45E4-8EC9-A1D6701510C1 Q50893020-02E2E309-D0FE-40F8-8030-7E4EA978ED06 Q51147808-4C554C8D-33E7-423C-899A-F1B1B2851B46 Q54942438-462AE5D3-28C0-46B8-BC6C-E0B344858A8F Q58801546-C1067723-18AF-4E22-A0E6-1FCE9DBC273A

P2860

Targeting SDF-1/CXCR4 to inhibit tumour vasculature for treatment of glioblastomas.

http://www.wikidata.org/entity/Q37876686

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 17 May 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Targeting SDF-1/CXCR4 to inhibit tumour vasculature for treatment of glioblastomas.

@en

Targeting SDF-1/CXCR4 to inhibit tumour vasculature for treatment of glioblastomas.

@nl

type

label

Targeting SDF-1/CXCR4 to inhibit tumour vasculature for treatment of glioblastomas.

@en

Targeting SDF-1/CXCR4 to inhibit tumour vasculature for treatment of glioblastomas.

@nl

prefLabel

Targeting SDF-1/CXCR4 to inhibit tumour vasculature for treatment of glioblastomas.

@en

Targeting SDF-1/CXCR4 to inhibit tumour vasculature for treatment of glioblastomas.

@nl

P1433

Q37876686-151E61EA-430F-4953-9E67-20325FCEA85C

P1476

Q37876686-A43241D2-8B57-4834-802E-550B638B9C63

P2093

Q37876686-42550B55-99DE-479B-B2D1-F2B0F848BADD

Q37876686-73BE4633-EF77-464F-AE2F-2DE9EFA23EDA

Q37876686-A12F0830-2BC0-4628-85E8-02CAA13AB975

P2860

Q37876686-014EBBE8-6B5B-43B7-B029-1246E38DF960

Q37876686-01678BA5-6F94-4519-B9BB-9CD85B345D1E

Q37876686-042A3DB2-383E-4521-B5EF-BA950A10D26E

Q37876686-13EFF833-2AB9-4255-BDCB-DD7D52DF78E5

Q37876686-1B7BF79C-75E4-466C-8348-0E22E811417D

Q37876686-35883676-33F5-49BE-B5A4-679CC8C99234

Q37876686-62A94ECC-ED4F-4CAB-A1C2-D169A8830909

Q37876686-6544F1D2-6661-4026-B51A-2AB12F1ABAC0

Q37876686-65AE9052-1F62-40DC-BB31-5EA396CD9DE6

Q37876686-6BF1C349-F3F8-441D-B088-3D36E7464A82

P2888

Q37876686-E4A89033-FB37-4E9C-A64E-29EF490F4EEA

P304

Q37876686-F86628A5-6E1E-4479-8EFF-A191C795D4D2

P31

Q37876686-5D819A64-603F-4D37-979D-42AD29BA2541

Q37876686-EEB74A34-8B47-41DB-A404-4BED5E3597EE

P356

Q37876686-B40B0C83-F821-4C09-ADF4-9AA3402089FF

P407

Q37876686-1A403EC8-56F9-40DB-B0D1-A19D05673265

P433

Q37876686-7D823B48-2534-4DC2-8FFF-BDF27E5CF782

P478

Q37876686-A54A0F45-4BFA-49EB-943E-15B3C5230FA1

P577

Q37876686-2DBA9203-907E-4F41-B689-0C7642DAF82B

Q37876686-6C533B1B-B61F-479B-BC74-2E340252BBC6

P5875

Q37876686-4E9BD429-8FC5-42A8-9DD1-788B37BCA414

P698

Q37876686-894C8652-71CA-4F4E-A0A9-136DE6D93701

P921

Q37876686-31F57751-DF8C-4FE1-89BD-8236D5C4E135

Q37876686-98CDCEB7-E311-4FA4-BE80-9EB443896099

Q37876686-9DBB03C0-A8F0-490D-A505-C719545F7642

Q37876686-ACE0725F-7979-419A-829F-CF1636BAD122

Q37876686-B81557C7-4989-4F81-9691-5ED7D46AD01A

Q37876686-F3954FC0-FCFC-4B06-9BAA-86CAD1EC4B38

Q37876686-FBCE328B-78EB-493D-BF28-736996FC175A

P932

Q37876686-335CA389-1427-4E22-8B2B-B1E1B4C0E6D3

P356

P1433

British Journal of Cancer

P1476

Targeting SDF-1/CXCR4 to inhibit tumour vasculature for treatment of glioblastomas.

@en

P2093

D A Vasquez-Medrano

http://www.w3.org/2001/XMLSchema#string

D Tseng

http://www.w3.org/2001/XMLSchema#string

J M Brown

http://www.w3.org/2001/XMLSchema#string

P2860

Involvement of chemokine receptors in breast cancer metastasis

A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development

CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature

Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice.

Bone marrow-derived circulating endothelial precursors do not contribute to vascular endothelium and are not needed for tumor growth

The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract

Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion

Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1

Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes

Radiotherapy suppresses angiogenesis in mice through TGF-betaRI/ALK5-dependent inhibition of endothelial cell sprouting

P2888

P304

1805-1809

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BJC.2011.169

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

104

http://www.w3.org/2001/XMLSchema#string

P577

2011-05-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2011-06-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51141458

http://www.w3.org/2001/XMLSchema#string

P698

21587260

http://www.w3.org/2001/XMLSchema#string

P921

cell surface receptor

membrane proteins

virus receptors

P932

3111201

http://www.w3.org/2001/XMLSchema#string